



Contact: Tricia J. Richardson  
Senior Manager, Investor Relations  
1 240-268-2031

## **NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference**

Rockville, MD (February 4, 2010)–PRNewswire-FirstCall/-Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12<sup>th</sup> Annual BIO CEO & Investor Conference on February 8<sup>th</sup>, 2010 at 10:00 am local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf=Astoria, New York. Dr. Singhvi will provide an overview of the company's business strategy, research and development progress and upcoming milestones. A link to the live audio only presentation can be accessed via the Company website at [www.novavax.com](http://www.novavax.com) under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

### **About Novavax**

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: [www.novavax.com](http://www.novavax.com).

### **About BIO CEO & Investor Conference**

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit [www.ceo.bio.org](http://www.ceo.bio.org).

###